Detection of residual lymph node metastases in high-risk papillary thyroid cancer patients receiving adjuvant I-131 therapy: The usefulness of F-18 FDG PET/CT

Clinical Nuclear Medicine

Volumn 35, Issue 1, 2010, Pages 6-11

  Kaneko, Koichiro ^a   Abe, Koichiro ^a   Baba, Shingo ^a   Isoda, Takuro ^a   Yabuuchi, Hidetake ^a   Sasaki, Masayuki ^b   Hatakenaka, Masamitsu ^a   Honda, Hiroshi ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

Author keywords

Adjuvant I 131 therapy; F 18 FDG PET CT; High risk PTC patients; Papillary thyroid cancer; Residual lymph node metastasis

Indexed keywords

FLUORODEOXYGLUCOSE F 18; IODINE 131; IOHEXOL; IOPAMIDOL; THYROGLOBULIN;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER DIAGNOSIS; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG ACCUMULATION; FEMALE; HIGH RISK POPULATION; HUMAN; LYMPH NODE METASTASIS; MALE; RETROSPECTIVE STUDY; THYROGLOBULIN BLOOD LEVEL; THYROID CANCER;

ADULT; AGED; CARCINOMA, PAPILLARY; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; IODINE RADIOISOTOPES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; RADIOPHARMACEUTICALS; RADIOTHERAPY, ADJUVANT; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; SUBTRACTION TECHNIQUE; THYROID NEOPLASMS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 75149147658     PISSN: 03639762     EISSN: None     Source Type: Journal    
DOI: 10.1097/RLU.0b013e3181c3b737     Document Type: Article

References (37)

1. Van Nostrand D, Wartofsky L. Radioiodine in the treatment of thyroid cancer. Endocrinol Metab Clin North Am. 2007;36:807-822.
2. Cooper DS, Doherty GM, Haugen BR, et al.. The American Thyroid Association Guidelines Taskforce. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2006;16:109-142.
3. Pacini F, Schlumberger M, Dralle H, et al.; European Thyroid Cancer Taskforce. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol. 2006;154:787-803.
4. Pacini F, Cetani F, Miccoli P, et al.. Outcome of 309 patients with metastatic differentiated thyroid carcinoma treated with radioiodine. World J Surg. 1994;18:600-604. (Pubitemid 24273863)
5. Tsang RW, Brierley JD, Simpson WJ, et al.. The effects of surgery, radioiodine, and external radiation therapy on the clinical outcome of patients with differentiated thyroid carcinoma. Cancer. 1998;82:375-388.
6. Tubiana M, Schlumberger M, Rougier P, et al.. Long-term results and prognostic factors in patients with differentiated thyroid carcinoma. Cancer. 1985;55:794-804. (Pubitemid 15173518)
7. Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med. 1994;97:418-428.
8. Haigh PI, Urbach DR, Rotstein LE. Extent of thyroidectomy is not a major determinant of survival in low- or high-risk papillary thyroid cancer. Ann Surg Oncol. 2005;12:81-89.
9. Bilimoria KY, Bentrem DJ, Ko CY, et al.. Extent of surgery affects survival for papillary thyroid cancer. Ann Surg. 2007;246:375-381.
10. DeGroot LJ, Kaplan EL, McCormick M, et al.. Natural history, treatment, and course of papillary thyroid carcinoma. J Clin Endocrinol Metab. 1990;71: 414-424.
11. Machens A, Hinze R, Thomusch O, et al.. Pattern of nodal metastasis for primary and reoperative thyroid cancer. World J Surg. 2002;26:22-28.
12. Mirallié E, Sagan C, Hamy A, et al.. Predictive factors for node involvement in papillary thyroid carcinoma. Univariate and multivariate analyses. Eur J Cancer. 1999;35:420-423.
13. Qubain SW, Nakano S, Baba M, et al.. Distribution of lymph node micrometastasis in pN0 well-differentiated thyroid carcinoma. Surgery. 2002;131: 249-256.
14. Harwood J, Clark OH, Dunphy JE. Significance of lymph node metastasis in differentiated thyroid cancer. Am J Surg. 1978;136:107-112.
15. Hay ID, McConahey WM, Goellner JR. Managing patients with papillary thyroid carcinoma: insights gained from the Mayo Clinic's experience of treating 2,512 consecutive patients during 1940 through 2000. Trans Am Clin Climatol Assoc. 2002;113:241-260.
16. Mazzaferri EL, Kloos RT. Clinical review 128: current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metab. 2001;86:1447-1463.
17. Simon D, Goretzki PE, Witte J, et al.. Incidence of regional recurrence guiding radicality in differentiated thyroid carcinoma. World J Surg. 1996;20:860-866.
18. Ito Y, Higashiyama T, Takamura Y, et al.. Risk factors for recurrence to the lymph node in papillary thyroid carcinoma patients without preoperatively detectable lateral node metastasis: validity of prophylactic modified radical neck dissection. World J Surg. 2007;31:2085-2091.
19. Woodrum DT, Gauger PG. Role of 131I in the treatment of well differentiated thyroid cancer. J Surg Oncol. 2005;89:114-121.
20. Mittendorf EA, Wang X, Perrier ND, et al.. Follow up of patients with papillary thyroid cancer: in search of the optimal algorithm. J Am Coll Surg. 2007;205:239-247.
21. Quon A, Fischbein NJ, McDougall IR, et al.. Clinical role of 18F-FDG PET/CT in the management of squamous cell carcinoma of the head and neck and thyroid carcinoma. J Nucl Med. 2007;48(suppl 1):58S- 67S.
22. Moog F, Linke R, Manthey N, et al.. Influence of thyroid-stimulating hormone levels on uptake of FDG in recurrent and metastatic differentiated thyroid carcinoma. J Nucl Med. 2000;41:1989-1995.
23. Chin BB, Patel P, Cohade C, et al.. Recombinant human thyrotropin stimulation of fluoro-D-glucose positron emission tomography uptake in welldifferentiated thyroid carcinoma. J Clin Endocrinol Metab. 2004;89:91-95.
24. Feine U, Lietzenmayer R, Hanke JP, et al.. Fluorine-18-FDG and iodine-131- iodide uptake in thyroid cancer. J Nucl Med. 1996;37:1468-1472.
25. Wang W, Larson SM, Tuttle RM, et al.. Resistance of -18F -fluorodeoxyglucose- avid metastatic thyroid cancer lesions to treatment with high-dose radioactive iodine. Thyroid. 2001;11:1169-1175.
26. Sobin LH, Wittekind C, eds. UICC: TNM Classification of Malignant Tumors. 6th ed. New York: Wiley-Liss; 2002.
27. Van Den Brekel MW, Stel HV, Castelijns JA, et al.. Cervical lymph node metastasis: assessment of radiologic criteria. Radiology. 1990;177:379-384.
28. Som PM, Brandwein M, Lidov M, et al.. The varied presentations of papillary thyroid carcinoma cervical nodal disease: CT and MR findings. Am J Neuroradiol. 1994;15:1123-1128.
29. Hundahl SA, Fleming ID, Fremgen AM, et al.. A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the US, 1985-1995. Cancer. 1998;83:2638-2648.
30. Ito Y, Miyauchi A. Lateral and mediastinal lymph node dissection in differentiated thyroid carcinoma: indications, benefits, and risks. World J Surg. 2007;31:905-915.
31. Sawka AM, Thephamongkhol K, Brouwers M, et al.. Clinical review 170: a systematic review and metaanalysis of the effectiveness of radioactive iodine remnant ablation for well-differentiated thyroid cancer. J Clin Endocrinol Metab. 2004;89:3668-3676.
32. Machens A, Holzhausen HJ, Dralle H. Skip metastases in thyroid cancer leaping the central lymph node compartment. Arch Surg. 2004;139:43-45.
33. Shammas A, Degirmenci B, Mountz JM, et al.. 18F-FDG PET/CT in patients with suspected recurrent or metastatic well-differentiated thyroid cancer. J Nucl Med. 2007;48:221-226.
34. Salvatore B, Paone G, Klain M, et al.. Fluorodeoxyglucose PET/CT in patients with differentiated thyroid cancer and elevated thyroglobulin after total thyroidectomy and 131I ablation. J Nucl Med Mol Imaging. 2008;52:2-8.
35. Ma C, Kuang A, Xie J, et al.. Possible explanations for patients with discordant findings of serum thyroglobulin and 131I whole-body scanning. J Nucl Med. 2005;46:1473-1480.
36. Hoffman EJ, Huang SC, Phelps ME. Quantitation in positron emission computed tomography: 1. Effect of object size. J Comput Assist Tomogr. 1979;3:299-308.
37. Schoder H, Yeung HW. Positron emission imaging of head and neck cancer, including thyroid carcinoma. Semin Nucl Med. 2004;34:180-197.